Physicians predict the impact new molecules will have on the EU psoriasis market
With several new molecules expected to launch onto the psoriasis market over the next 12 months, we recently asked our panel of 200 EU-based dermatologists the impact this may have on their future prescribing behaviour.
Utilising our panel of 200 EU based dermatologists, our results reveal that 74% of physicians are aware of new classes and/or drugs in development for the treatment of Psoriasis (PsO) without prompting. IL-17 inhibitors were the most commonly mentioned drugs cited by 75% of respondents, followed by JAK-inhibitors and PDE-inhibitors. However, when physicians were prompted about their familiarity with key pipeline agents they reported low scores overall, suggesting that more awareness and improvement of physicians’ knowledge of these late stage compounds are needed to achieve growth in the market.
Maximising uptake of biosimilars in an evolving market
Our client was developing biosimilars of two biologic drugs and wanted to understand the likely market potential for their assets.